Columbia, MD (July 12, 2023) – Three Twenty-One is pleased to share that its client, Atlas Clinical Research (“Atlas”), has completed its acquisition of Suburban Research Associates (“Suburban”). Three Twenty-One acted as Atlas’ exclusive buy-side advisor in this transaction.
Atlas launched in April 2023 to build a high-performing clinical research site network through acquisition and organic growth, leveraging a centralized platform that will solve critical pain points for pharmaceutical sponsors. Atlas is a Biotechnology Research company with a mission to bridge the gap between “what is and what’s possible.” With a focus on therapeutic areas, Atlas operates a network of sites that aim to drive clinical trial success and advance pioneering medical treatments.
Over three decades, sponsors and CROs have recognized the individual investigator sites within Atlas's portfolio as distinguished hubs for conducting research in internal medicine, central nervous system disorders, gastrointestinal ailments, and infectious diseases.
"The network that Atlas is building provides Suburban with the opportunity to expand and grow to scale through integrated technology use, long-tenured clinical trial management expertise and streamlined systems to serve a larger and more diverse population in Chester & Delaware Counties with better-quality results," said Dr. Shivkumar Hatti, leader of the Suburban site conducting Phase II-IV psychiatric research from its two locations in Media and West Chester, PA. "We pride ourselves on our patient care, and we are thrilled that this partnership with Atlas matches that mission to deliver innovative treatment to the market with safety and speed at the forefront."
"We are delighted to welcome Dr. Hatti and his team to the Atlas Clinical Research family. Suburban has a long, impressive history of excellence that contributes to the mission and strategy at Atlas Clinical Research," said Mark Scullion, CEO of Atlas. "As part of the Atlas network, Suburban can continue this legacy while better addressing the evolving landscape of psychiatric trials and accelerating treatment by serving trial patients with efficiency."
About Atlas Clinical Research
Atlas operates a therapeutically driven clinical site network centered on streamlined processes and integrated technology. These sites, along with their physicians, serve as a bridge connecting patients and their families to new treatments that may improve their quality of life. Specializing in infectious disease, CNS disorders, gastroenterology, and internal medicine, Atlas aims to expand its reach across the United States to cater to a wide-ranging and diverse population of waiting patients. Partnering with biopharma sponsors, Atlas is committed to expediting the advancement of healthcare, prioritizing speed, data integrity, and patient care across the portfolio. Read more: www.atlas-clinical.com
About Three Twenty-One Capital Partners
Three Twenty-One Capital Partners is headquartered in the Baltimore-Washington Metro area, with offices in Colorado, Florida, and New York. Three Twenty-One Capital Partners specializes in providing investment banking services to family and founder-led businesses in the lower middle market. Three Twenty-One Capital Partners’ team has completed engagements with over $15 billion in transaction value. Further information is available at www.321capital.com.